BHV3000-401: An Open-label, Intermediate-size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine

Pfizer0 个研究点开始时间: 2019年5月1日最近更新: 2023年2月23日

适应症

试验速览

阶段: 不适用
状态: No Longer Available
发起方: Pfizer

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

The purpose of this protocol is to allow subjects who completed any BHV3000 (rimegepant) clinical study to continue to have access to rimegepant while collecting ongoing safety data.

(NOTE: ONLY FOR PATIENTS who participated in a previous BHV-3000/Rimegepant Clinical Trial in the past)

研究设计

研究类型: Expanded Access

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•1.Subjects who have completed any BHV3000 (rimegepant) clinical study without significant protocol violations.

排除标准

•History of basilar migraine or hemiplegic migraine
•History with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease
•HIV history
•Uncontrolled hypertension or uncontrolled diabetes
•Current diagnosis of major depression, other pain syndromes, psychiatric conditions (e.g., schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments
•History of gastric, or small intestinal surgery, or has a disease that causes malabsorption

研究者

发起方

Pfizer

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

3 期

Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of MigraineAcute Migraine

NCT04574362Pfizer1,648

已完成

2 期

Open Label Safety Study in Acute Treatment of MigraineMigraine, With or Without Aura

NCT03266588Pfizer3,019

Approved For Marketing

不适用

Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyMetastatic Castration-Resistant Prostate Cancer

NCT01606982Astellas Pharma Global Development, Inc.

Unknown

2 期

Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)Major Depressive Disorder

NCT06423781Biohaven Therapeutics Ltd.480

No Longer Available

不适用

Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisALSLou Gehrig DiseaseLou Gehrig's DiseaseLou-Gehrigs DiseaseMotor Neuron Disease, Amyotrophic Lateral Sclerosis

NCT03537807Biohaven Pharmaceuticals, Inc.